Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity.
Among features of motor disorders in children, spasticity is associated with considerable morbidity and problems in care, particularly in severely affected patients. Intrathecal baclofen (ITB) has been increasingly used as a relatively specific treatment modality for spasticity. To date, most of the evidence for its use in paediatric patients has come from retrospective and uncontrolled studies, although randomised, controlled trials of screening ITB and ITB therapy itself have recently been published. This consensus statement on the use of ITB in paediatric patients with spasticity was developed on the basis of currently available evidence, with the aim of providing information for clinicians, promoting an expert opinion and a consistent approach to the management of these patients and emphasising the need for further prospective, large-scale studies.
Dan
Bernard
B
Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université libre de Bruxelles, 15 Avenue JJ Crocq, 1020 Brussels, Belgium. bernard.dan@ulb.ac.be
Motta
Francesco
F
Vles
Johann S H
JS
Vloeberghs
Michael
M
Becher
Jules G
JG
Eunson
Paul
P
Gautheron
Vincent
V
Lütjen
Sonnhild
S
Mall
Volker
V
Pascual-Pascual
Samuel Ignacio
SI
Pauwels
Petra
P
Røste
Geir Ketil
GK
D001418:Baclofen / Q000627:therapeutic use*; D032921:Consensus; D017408:Guidelines as Topic; D006801:Humans; D007278:Injections, Spinal / Q000379:methods; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy*; D010372:Pediatrics
D009125:Muscle Relaxants, Central; D001418:Baclofen